Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pulmatrix, Inc. PULM
$2.79
-$0.12 (-4.45%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
10841117.00000000
-
week52high
7.50
-
week52low
2.70
-
Revenue
6071000
-
P/E TTM
-1
-
Beta
0.75501700
-
EPS
-5.73000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 13:05
Описание компании
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 30 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Batycky Richard P. | A | 1700 | 1700 | 26 янв 2023 г. |
| Varadan Anand | A | 1700 | 1700 | 26 янв 2023 г. |
| Bazemore Todd | A | 1700 | 1700 | 26 янв 2023 г. |
| Higgins Michael J | A | 2436 | 2436 | 26 янв 2023 г. |
| Cabell Christopher | A | 1700 | 1700 | 26 янв 2023 г. |
| Raad Teofilo David | A | 34900 | 34900 | 26 янв 2023 г. |
| Siegert Michelle | A | 9900 | 9900 | 26 янв 2023 г. |
| Wasilewski Margaret | A | 11400 | 11400 | 26 янв 2023 г. |
| Wasilewski Margaret | A | 21060 | 21060 | 01 мар 2022 г. |
| Batycky Richard P. | A | 22100 | 22100 | 27 янв 2022 г. |
Новостная лента
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
PRNewsWire
23 янв 2023 г. в 09:05
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the acceptance of an abstract for presentation at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting, to be held February 24-27, 2023 in San Antonio, Texas.